NASDAQ: BLUE | Healthcare / Biotechnology / USA |
28.28 | -1.44 | -4.85% | Vol 2.44M | 1Y Perf -46.19% |
Apr 16th, 2021 16:00 DELAYED |
BID | 28.01 | ASK | 28.36 | ||
Open | 29.32 | Previous Close | 29.72 | ||
Pre-Market | - | After-Market | 28.19 | ||
- - | -0.09 -0.32% |
Target Price | 50.17 | Analyst Rating | Strong Buy 1.50 | |
Potential % | 77.40 | Finscreener Ranking | ★★★★+ 58.30 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 56.75 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 64.14 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Market Cap | 1.90B | Earnings Rating | Buy | |
Price Range Ratio 52W % | 8.37 | Earnings Date | 10th May 2021 |
Today's Price Range 27.9929.84 | 52W Range 24.2472.50 | 5 Year PE Ratio Range -11.30-6.90 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 0.43% | ||
1 Month | -8.77% | ||
3 Months | -44.03% | ||
6 Months | -49.59% | ||
1 Year | -46.19% | ||
3 Years | -83.47% | ||
5 Years | -43.87% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -37.62 | |||
ROE last 12 Months | -44.93 | |||
ROA (5Y Avg) | -29.67 | |||
ROA last 12 Months | -33.79 | |||
ROC (5Y Avg) | -33.88 | |||
ROC last 12 Months | -38.67 | |||
Return on invested Capital Q | -12.30 | |||
Return on invested Capital Y | -41.48 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 11.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-2.90 | ||||
1.43 | ||||
8.21 | ||||
5.70 | ||||
-6.90 | ||||
-7.56 | ||||
1.46 | ||||
20.18 | ||||
980.13M | ||||
Forward PE | -2.84 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
5.80 | ||||
6.00 | ||||
0.11 | ||||
0.14 | ||||
- | ||||
Leverage Ratio | 1.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
97.90 | ||||
-261.50 | ||||
-253.70 | ||||
-1 654.20 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
228.87M | ||||
3.41 | ||||
64.59 | ||||
92.30 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | -3.02 | -3.01 | 0.33 |
Q03 2020 | -3.07 | -2.94 | 4.23 |
Q02 2020 | -1.91 | -0.36 | 81.15 |
Q01 2020 | -3.94 | -3.64 | 7.61 |
Q04 2019 | -3.81 | -4.04 | -6.04 |
Q03 2019 | -3.53 | -3.73 | -5.67 |
Q02 2019 | -3.03 | -3.55 | -17.16 |
Q01 2019 | -2.80 | -2.99 | -6.79 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | -3.05 | 0.65 | Positive |
6/2021 QR | -2.98 | -0.34 | Negative |
12/2021 FY | -11.73 | -0.51 | Negative |
12/2022 FY | -9.90 | -2.91 | Negative |
Next Report Date | 10th May 2021 |
Estimated EPS Next Report | -3.02 |
Estimates Count | 12 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 2.44M |
Shares Outstanding | 67.14M |
Trades Count | 15.07K |
Dollar Volume | 226.42M |
Avg. Volume | 2.20M |
Avg. Weekly Volume | 1.30M |
Avg. Monthly Volume | 1.78M |
Avg. Quarterly Volume | 2.36M |
bluebird bio Inc. (NASDAQ: BLUE) stock closed at 28.28 per share at the end of the most recent trading day (a -4.85% change compared to the prior day closing price) with a volume of 2.45M shares and market capitalization of 1.90B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1213 people. bluebird bio Inc. CEO is Nick Leschly.
The one-year performance of bluebird bio Inc. stock is -46.19%, while year-to-date (YTD) performance is -34.64%. BLUE stock has a five-year performance of -43.87%. Its 52-week range is between 24.24 and 72.5, which gives BLUE stock a 52-week price range ratio of 8.37%
bluebird bio Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 1.43, a price-to-sale (PS) ratio of 8.21, a price to cashflow ratio of 5.70, a PEG ratio of 2.32, a ROA of -33.79%, a ROC of -38.67% and a ROE of -44.93%. The company’s profit margin is -%, its EBITDA margin is -253.70%, and its revenue ttm is $228.87 Million , which makes it $3.41 revenue per share.
Of the last four earnings reports from bluebird bio Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-3.02 for the next earnings report. bluebird bio Inc.’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for bluebird bio Inc. is Strong Buy (1.5), with a target price of $50.17, which is +77.40% compared to the current price. The earnings rating for bluebird bio Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
bluebird bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
bluebird bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.59, ATR14 : 2.26, CCI20 : -72.44, Chaikin Money Flow : -0.25, MACD : -2.88, Money Flow Index : 54.43, ROC : -1.19, RSI : 40.47, STOCH (14,3) : 17.94, STOCH RSI : 0.68, UO : 46.52, Williams %R : -82.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of bluebird bio Inc. in the last 12-months were: Alison Cecily Finger (Sold 2 102 shares of value $97 569 ), Andrew Obenshain (Sold 817 shares of value $23 660 ), David Davidson (Sold 4 376 shares of value $188 533 ), Douglas G. Cole (Sold 3 706 shares of value $163 401 ), Katy Burnett (Sold 641 shares of value $20 256 ), Kory J. Wentworth (Sold 832 shares of value $54 610 ), Nick Leschly (Sold 14 566 shares of value $685 783 ), Philip D. Gregory (Sold 3 974 shares of value $172 055 ), William D. Baird (Sold 2 858 shares of value $117 624 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Moderate Buy |
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.
CEO: Nick Leschly
Telephone: +1 339 499-9300
Address: 60 Binney Street, Cambridge 02142, MA, US
Number of employees: 1 213
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.